Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice by Tarbell, Kristin V. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 1,  January 22, 2007  191–201  www.jem.org/cgi/doi/10.1084/jem.20061631
191
Nonobese diabetic (NOD) mice develop spon-
taneous autoimmune diabetes, particularly in 
females. Lymphocytes begin to infi  ltrate  the 
pancreatic islets between 4 and 9 wk of age, 
whereas overt diabetes caused by destruction 
of insulin-producing β cells (defi  ned by the 
  inability to maintain normal blood glucose 
  levels) does not occur until 11–25 wk of age. 
Many treatments are able to prevent diabetes 
in NOD mice when given weeks before dia-
betes develops (1). However, few treatments 
have been found that can inhibit diabetes de-
velopment at the time of onset or reverse dia-
betes after hyperglycemia is observed (2–6). 
These two later pathogenic stages parallel po-
tential intervention points in human type 1 
  diabetes. Identifying tolerance mechanisms that 
work at these points is important both for un-
derstanding the disease and for translating 
  fi  ndings into clinical studies and results. In hu-
mans, antigen nonspecifi  c anti-CD3 has been 
used with some effi   cacy (2, 7). Adding antigen 
specifi  city may improve treatment, and this 
  issue is beginning to be addressed in mouse 
models, where treatment of diabetes is seen 
with lower doses of anti-CD3 if given along 
with islet peptides (6).
Recently, we have shown that antigen-
pulsed DCs and IL-2 can expand functional 
antigen-specifi  c T reg cells (8–10). To study 
T reg cells in the context of NOD mice, we 
have used CD4+ CD25+ TCR transgenic 
T cells from the BDC2.5 line (11). BDC2.5 
T  cells recognize a peptide that mimics an 
  unidentifi  ed natural antigen in islet β cells (12). 
DC-expanded, BDC2.5 islet-specifi  c  T reg 
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Most treatments that prevent autoimmune diabetes in nonobese diabetic (NOD) mice 
require intervention at early pathogenic stages, when insulitis is fi  rst developing. We tested 
whether dendritic cell (DC)–expanded, islet antigen–specifi  c CD4+ CD25+ suppressor T cells 
could treat diabetes at later stages of disease, when most of the insulin-producing islet 
𝗃 cells had been destroyed by infi  ltrating lymphocytes. CD4+ CD25+ CD62L+ regulatory 
T cells (T reg cells) from BDC2.5 T cell receptor transgenic mice were expanded with antigen-
pulsed DCs and IL-2, and were then injected into NOD mice. A single dose of as few as 
5 × 104 of these islet-specifi  c T reg cells blocked diabetes development in prediabetic 
13-wk-old NOD mice. The T reg cells also induced long-lasting reversal of hyperglycemia in 
50% of mice in which overt diabetes had developed. Successfully treated diabetic mice had 
similar responses to glucose challenge compared with nondiabetic NOD mice. The successfully 
treated mice retained diabetogenic T cells, but also had substantially increased Foxp3+ 
cells in draining pancreatic lymph nodes. However, these Foxp3+ cells were derived from 
the recipient mice and not the injected T reg cells, suggesting a role for endogenous T reg 
cells in maintaining tolerance after treatment. Therefore, inoculation of DC-expanded, 
antigen-specifi  c suppressor T cells has considerable effi  cacy in ameliorating ongoing 
  diabetes in NOD mice.
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cells are >100-fold more potent in preventing diabetes than 
T reg cells derived from a   polyclonal NOD T cell repertoire, 
indicating the importance of antigen specifi  city for T reg cell 
function (9). Islet-specifi  c BDC T reg cells can also be ex-
panded using beads coated with either mitogenic antibodies 
or tetramers, but it has not been determined if these bead-
expanded T reg cells express high levels of Foxp3 protein 
(a transcription factor important for T reg cell function [13]) 
or if these cells are as potent as DC-expanded T reg cells for 
inhibition of diabetes (14, 15).
In some instances, islet-specifi   c T reg cells have been 
shown to treat later stages of diabetes. In one experiment, in 
addition to treatment with T reg cells, islet transplant was 
used to rescue insulin production (14). In another experi-
ment, the T reg cells were artifi  cially induced by transfecting 
the T cells with Foxp3 (16). Both of these systems have 
drawbacks for potential translation into human therapy, the 
former because of the limited availability of islets for trans-
plantation and the later because of the demands of human 
gene therapy. Therefore, it is important to establish the effi   -
cacy of naturally occurring islet-specifi  c T reg cells in a cell 
therapy model and to use these cells without the addition of 
other demanding strategies.
In this study, we show that DC-expanded, islet-specifi  c 
T reg cells can block diabetes months after initiation of insu-
litis and restore long-term normoglycemia when given to 
  recent-onset diabetic mice. When compared with untreated 
diabetic controls, the diabetic mice successfully treated with 
T reg cells respond better in a glucose tolerance test and have 
increased numbers of Foxp3+ cells when compared with un-
treated diabetic mice. Interestingly, the Foxp3+ cells in treated 
mice are not from the injected T reg cells but derive from the 
recipient T cell repertoire.
RESULTS
After expansion with DCs, CD4+ CD25+ CD62L+ cells 
from BDC2.5 mice retain high Foxp3 and CD62L expression 
and divide in the pancreatic lymph node
Previously, we showed that bone marrow–derived DCs 
loaded with cognate peptide were eff  ective at inducing ex-
pansion of CD4+ CD25+ T cells (8, 9). In this study, we fur-
ther separated this population before expansion, according to 
expression of the lymph node homing and memory/activation 
marker CD62L, into CD4+ CD25+ CD62L+ and CD4+ 
CD25+ CD62L− (Fig. 1 A). CD62L+ cells can home to 
lymph nodes, which may be important for T reg cell function 
Figure 1.  Characterization of DC-expanded T reg cells from 
BDC2.5 NOD mice. (A) CD25-enriched cells from NOD BDC2.5 mice 
  before (top) and after sorting for CD4+ CD25+ CD62L− (middle) or CD4+ 
CD25+ CD62L+ (bottom) cells. (B) Foxp3 expression on CD4+ CD25+ 
CD62L+ (top) or CD4+ CD25+ CD62L− (bottom) cells before and after 
expansion with DCs. (C) CD62L expression on CD4+ CD25+ CD62L− (left) 
and CD4+ CD25+ CD62L+ (right) BDC T cells after expansion with DCs. 
(D) DC-expanded BDC T reg cells were labeled with CFSE and injected into 
either 5-wk-old or 12-wk-old NOD females. CFSE and anti-BDC clonotype 
stainings are shown on cells gated on size and CD4 from lymph nodes or 
pancreatic lymph nodes. The percentage of cells in the indicated gates is 
shown. Results are representative of at least three experiments.JEM VOL. 204, January 22, 2007  193
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(17, 18). After expansion with DCs, the majority of CD62L+ 
cells maintained high levels of CD62L and Foxp3. DC-
  expanded CD62L− T cells expressed similar levels of Foxp3 
but lower CD62L when compared with the CD62L+ cells 
(Fig. 1, B and C).
BDC2.5 T cells proliferate and expand in the pancreatic 
lymph node, but not other lymph nodes (14, 19), most likely 
because antigens from islet β cells are presented by DCs in 
the draining pancreatic lymph node (20). To check the in 
vivo activity of DC-expanded CD4+ CD25+ cells, these cells 
were labeled with carboxyfl  uorescein diacetate succinimidyl 
ester (CFSE) and transferred into NOD mice. BDC2.5 T 
cells were followed using a clonotype anti  body specifi  c for 
the BDC2.5 TCR. 10 d later, few BDC clonotype+ cells 
  remained in the peripheral lymph nodes, and most had not 
diluted CFSE. In contrast, in the pancreatic lymph node, 
  clonotype+ T cells accumulated, and a substantial fraction 
had undergone one or more divisions, as indicated by lower 
CFSE fl  uorescence (Fig. 1 D). Therefore, like conventional 
T cells, the DC-expanded T reg cells home to and proliferate 
in antigen-draining lymph nodes, presumably in response to 
DCs presenting cognate antigen (21).
Some previous studies have shown that the number of 
T reg cells in NOD mice decreases with age (22, 23). An im-
paired ability of T reg cells to proliferate in vivo is one expla-
nation to account for this observation. Other studies have 
observed constant numbers of T reg cells in diff  erent ages 
of NOD female mice (22, 24). In our observation, the ability 
of the DC-expanded BDC T reg cells to proliferate in 
  response to antigen in the pancreatic lymph node did not 
substantially alter with the age of the host. At 5 wk, which 
correlates with the onset of insulitis, and at 12 wk, which 
correlates with onset of destructive diabetes, similar levels 
of CFSE dilution were observed (Fig. 1 D). Therefore, no 
alteration in environment occurs in the pancreatic lymph 
node during diabetes pathogenesis that inhibits the ability of 
T reg cells to proliferate.
Islet-specifi  c T reg cells block spontaneous diabetes 
when given just before the time of diabetes onset
We tested whether these islet-specifi   c T reg cells from 
BDC2.5 mice were eff  ective at blocking the development 
of spontaneous diabetes in 13-wk-old female NOD mice. 
This time point is late in the pathogenic process, when 
  diabetes begins and islet infl  ammation has usually progressed 
for at least 6 wk (25). We found that one dose of 3 × 105 
DC-expanded BDC2.5 CD4+ CD25+ CD62L+ T cells 
could signifi   cantly delay diabetes when given at 13 wk; 
mice receiving these cells only began to slowly develop dia-
betes after 30 wk. In contrast, the CD4+ CD25+ CD62L− 
population had no eff  ect (Fig. 2 A). In a second preven-
tion experiment, smaller numbers of DC-expanded CD4+ 
CD25+ CD62L+ cells from BDC2.5 mice were given 
to prediabetic mice. Groups receiving 2 × 105, 5 × 104, 
or 104 cells had a signifi  cant delay in diabetes. Again, DC-
expanded CD4+ CD25+ CD62L− cells had no eff  ect on 
diabetes development (Fig. 2 B). In addition, CD62L+ T 
reg cells from NOD mice expanded with DCs and anti-
CD3 were not able to inhibit diabetes development (Fig. 
2 C), showing the need for islet-antigen specifi  city for toler-
ance induction, as observed in the NOD.scid transfer model 
(9). Therefore, small numbers of islet-specifi  c CD62L+ T 
reg cells can block diabetes when given just before the mice 
normally develop diabetes.
Figure 2.  CD25+ CD62L+ T cells from BDC2.5 mice protect from 
diabetes development when given to prediabetic mice. 13-wk-old 
nondiabetic NOD females were given the indicated numbers of DC-
 expanded  CD4+ CD25+ CD62L+ or CD4+ CD25+ CD62L− T cells from 
BDC2.5 (A–C) or NOD (C) mice, and diabetes was monitored weekly. The 
number of mice in each group is indicated in parentheses. In A, P = 0.0373 
for PBS versus CD4+ CD25+ CD62L+ cells.194  DC-EXPANDED BDC2.5 T REG CELLS REVERSE DIABETES IN NOD MICE | Tarbell et al.
Treatment of diabetic mice with islet-specifi  c T reg cells
We next turned to newly diabetic mice with elevated blood 
glucose levels. We determined the eff  ectiveness of using a 
combination of islet-specifi  c T reg cells and short-term insu-
lin replacement using insulin pellets, which release insulin for 
 3 wk. In addition, we used the gut-derived glucagon-like 
peptide 1 (GLP-1), which stimulates insulin secretion (26) 
and lowers circulating glucose levels in type 2 diabetes pa-
tients and healthy human subjects (27, 28). Recently, it has 
been reported that GLP-1 promotes the growth and survival 
of the pancreatic β cells and decreases the metabolic require-
ment for insulin secretion (29).
In the fi  rst treatment experiment, recent-onset diabetic 
NOD mice were given insulin and GLP-1 for 3 wk to 
  maintain normal glucose levels, while the induction of 
  immune tolerance by the injected suppressor T cells takes 
place. Groups were matched for the range of starting blood 
glucose. In all four control mice that received GLP-1 but 
not T reg cells, the blood glucose rose again soon after 
  exogenous insulin was not available. In contrast, in three 
Figure 3.  DC-expanded BDC T reg cells reverse hyperglycemia in 
recent-onset diabetic mice. (A) Diabetic female NOD mice were given 
insulin pellets and 1.5 × 106 BDC T reg cells, where indicated at days 
0 and 14, and GLP-1. Blood glucose levels were measured on the days 
indicated. Each symbol represents an individual mouse in the treatment 
protocol indicated on the panel. (B) Diabetic female NOD mice were given 
BDC T reg cells (left) or BDC T reg cells and exendin-4 (right). Insulin pel-
lets were given to maintain blood glucose levels below 250 mg/dl for 42 d, 
at which time all pellets were removed (as indicated by the arrows). Blood 
glucose levels were measured on the days indicated (for clarity, blood 
glucose levels during insulin treatment are not shown). The ratio of suc-
cessfully treated/total in each group is shown in parentheses. Different 
symbols represent individual mice treated as indicated in the panel. 
(C) Initial blood glucose levels in diabetic mice that responded (left) or did 
not respond (right) to treatment with T reg cells and GLP-1 or exendin-4. 
Horizontal lines represent the means. (D) Summary of recent-onset diabetic 
NOD mice treated with BDC T reg cells. Successfully treated mice main-
tained long-term normoglycemia without exogenous insulin treatment. 
P = 0.004 for BDC T reg cells + exendin-4 or GLP-1 versus exendin-4 or 
GLP-1; P = 0.0429 for BDC T reg cells versus exendin-4 or GLP-1.JEM VOL. 204, January 22, 2007  195
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out of fi  ve mice that received T reg cells and GLP-1, the 
blood glucose readings stayed below 200 mg/dL for an ad-
ditional 90 d (Fig. 3 A).
Because of a concern of potential residual exogenous 
insulin secretion from the pellets after the presumed cessa-
tion of its release at the 3-wk interval, insulin pellets were 
removed after 40 d in subsequent experiments. In addition, 
exendin-4, a more stable analogue of GLP-1, was given i.p. 
where indicated (30). Similar results to the ones shown in 
Fig. 3 A were obtained (Fig. 3 D and Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061631/DC1). 
To determine the importance of adding exendin-4, recent-
onset diabetic mice were given T reg cells alone or T reg 
cells and exendin-4. T reg cells alone could restore normo-
glycemia (Fig. 3, B and D). In our colony, diabetic NOD 
mice given no treatment do not become normoglycemic for 
long periods of time. An example of blood glucose levels 
from one cohort of NOD female mice followed from 12–25 
wk is shown in Fig. S2.
Interestingly, mice successfully treated with T reg cells 
and exendin-4 started the experiment with a statistically sig-
nifi  cant lower mean level of initial blood glucose than those 
mice in which the same treatment failed; responders had a 
mean level of 365 mg/dl as compared with 467 mg/dl for 
nonresponders (Fig. 3 C). This suggests that the amount of 
residual β cell mass may be limiting the ability to treat diabetic 
mice via immune tolerance. Because groups were matched 
for initial blood glucose, as expected, mice given exendin-4 
alone had the same mean initial blood glucose level (421 mg/dl) 
as mice given T reg cells and exendin-4 (including responders 
and nonresponders).
In all, a total of 41 mice were followed long term after 
treatment, and 14 out of 30 mice receiving T reg cells were 
successfully treated, whereas all 11 mice that did not receive 
T reg cells failed to maintain long-term normoglycemia (Fig. 
3 D and not depicted). We conclude that diabetes can be re-
versed after onset by treatment with a combination of CD4+ 
CD25+ CD62L+ T reg cells from BDC2.5 mice and insulin, 
with or without GLP-1 receptor agonists.
Characterization of insulin response to glucose challenge 
and insulitis in T reg cell–treated mice
Maintenance of normoglycemia among diabetic mice treated 
with insulin, GLP-1, and islet-specifi  c T reg cells suggests 
some restoration of β cell function. One measure of β cell 
function that has been shown to correlate with β cell mass is 
a glucose tolerance test: determining the time for mice to re-
turn to baseline blood glucose levels after i.p. glucose injec-
tion; better β cell function (and greater β cell mass) correlates 
with a faster response (31). We compared T reg cell–treated 
mice with three control groups: 12–15-wk-old nondiabetic, 
30-wk-old nondiabetic, and recently diabetic NOD mice. 
The younger nondiabetic control mice exhibit a faster insulin 
response, as indicated by a more rapid return of blood glucose 
levels to baseline, than either the older nondiabetic or dia-
betic control mice. The response in the T reg cell–treated 
mice was similar to the prediabetic mice; one example of 
each group is shown in Fig. 4 A. This response can be repre-
sented by the area under the curve: a more rapid response 
corresponding to increased insulin secretion will provide a 
lower area. When summarized over numerous experiments, 
the response of T reg cell–treated mice to glucose challenge 
was signifi  cantly lower than the diabetic controls and not sig-
nifi  cantly diff  erent from 12–15-wk-old prediabetic NOD fe-
males (Fig. 4 B), suggesting that the treated mice regained the 
ability to secrete enough insulin to control the elevated glu-
cose levels that occur after feeding, potentially via increased 
β cell mass.
The level of insulitis in DC-expanded T reg cell–treated 
mice was also compared with diabetic or 12–15- or 30-wk- 
old nondiabetic NOD females. In all groups, a mix of healthy 
and infi   ltrated islets was observed (Fig. S3, available at 
Figure 4.  T reg cell–treated mice have a normal response to glucose 
challenge. Glucose tolerance test in T reg cell–treated diabetic mice. 
Blood glucose levels were followed for 90 min after i.p. glucose injection 
into female NOD mice either successfully treated after diabetes onset with 
BDC T reg cells (closed squares), 12–15-wk-old (open circles) or 30 wk-old 
nondiabetic mice (closed circles), or diabetic mice (closed   diamonds). One 
example of each group is shown in (A). For all mice tested, the area under 
the curve as shown in A was calculated, and the means of each group are 
indicated by the horizontal lines (B). P ≤ 0.0001 for both T reg cell–treated 
versus diabetic mice and 12–15-wk-old nondiabetic versus diabetic mice; 
P = 0.027 for 30-wk-old nondiabetic versus diabetic mice.196  DC-EXPANDED BDC2.5 T REG CELLS REVERSE DIABETES IN NOD MICE | Tarbell et al.
http://www.jem.org/cgi/content/full/jem.20061631/DC1). 
Comparable lymphocytic infi  ltrates were found in the salivary 
glands of all mice tested (unpublished data).
Islet-specifi  c T reg cell–treated mice contain both 
pathogenic cells and increased T reg cells
Successfully treated mice were further characterized to look 
for phenotypes that correlate with treatment. Foxp3 is a tran-
scription factor that can be used to identify T reg cells, espe-
cially in infl  ammatory conditions where some CD4+ CD25+ 
cells are recently activated T cells (13). Both the percentage 
of CD4+ cells that were Foxp3+ and the total number of 
Foxp3+ CD4+ T cells was signifi   cantly higher in lymph 
nodes of T reg cell–treated mice as compared with 12–15-
wk-old NOD females, either diabetic or nondiabetic. This 
diff  erence was especially pronounced in the draining pancre-
atic lymph node, where the T reg cell–treated mice had as 
high as 30% Foxp3+ cells within the CD4+ T cell   population. 
The mean percentage was 25% in treated mice as compared 
with 15% in diabetic or 14% in nondiabetic controls (Fig. 5, 
A and B; and not depicted).
To determine if pathogenic T cells were still present in 
the treated mice, spleen cells from treated mice were trans-
ferred to NOD.scid mice, and diabetes development was 
  followed. Mice injected with spleen cells from diabetic control 
mice developed diabetes between 30 and 80 d after transfer, 
and NOD.scid mice injected with spleen cells from T reg 
cell–treated mice developed diabetes in a similar timeframe 
(Fig. 5 C). Therefore, mice successfully treated with DC-
  expanded T reg cells retain pathogenic cells capable of causing 
diabetes but also have increased numbers of T reg cells.
Foxp3+ cells in mice successfully treated with T reg cells 
derive from the diabetic recipient
To determine whether the increase in Foxp3+ cells was 
caused by the expansion of injected cells, we injected DC-
expanded T reg cells from BDC NOD Thy1.1 mice and 
  exendin-4 into diabetic NOD Thy1.2 mice according to the 
treatment protocol described in Fig. 3 B. 10 d after the insu-
lin pellets were removed, mice that responded to T reg cell 
treatment (with blood glucose levels >250 mg/dl) were 
characterized for expression of Thy1.1 and Foxp3. However, 
in those treated mice almost none of the CD4+ Foxp3+ cells 
in lymphoid organs were Thy1.1+, and CD4+ T cells in the 
pancreas of treated mice were Thy1.1−, indicating that they 
derived from the diabetic host and not the injected T reg cells 
(Fig. 6, A and B; and not depicted). In a similar experiment, 
no notable population of Thy1.1 T cells was found at a later 
time point after successful treatment with Thy1.1+ T reg 
cells (unpublished data). As a positive control, DC-expanded 
CD62L+ or CD62L− T reg cells from BDC2.5 Thy1.1 mice 
were injected into prediabetic NOD Thy1.2 mice. After 
1 wk, CD4+ Thy1.1+ T cells could be found in both the 
pancreatic lymph node and the pancreas (Fig. 6, C and D). 
In addition, pancreas sections from Thy1.2+ diabetic mice 
treated with Th1.1+ T reg cells were stained with antibodies 
Figure 5.  Pathogenic and T reg cells in lymphoid organs of T reg 
cell–treated diabetic mice. (A) Cells from pancreatic lymph nodes, 
  peripheral lymph nodes, or spleens of female NOD mice either nondiabetic 
(top) or successfully treated with BDC T reg cells (bottom) were harvested 
and stained for CD4-FITC, CD25-APC, and Foxp3-PE. The plots shown have 
been gated fi  rst on size and then on CD4+ cells. The percentage of cells 
in the two gates shown (CD25+ Foxp3− and Foxp3+) are indicated on 
the plots. (B) Summary of the percentage of Foxp3+ cells of CD4+ cells 
(as gated in A) for BDC T reg cell–treated (closed squares), diabetic (closed 
diamonds), or nondiabetic (open circles) NOD female mice. Horizontal 
lines represent the means. In both pancreatic and peripheral lymph nodes, 
P < 0.004 for T reg cell–treated versus either diabetic or nondiabetic 
mice. (C) Spleen cells from either newly diabetic mice (closed circles), 
diabetic mice successfully treated with BDC T reg cells (triangles), or 
  nondiabetic mice (open circles) were transferred to NOD.scid females. 
Development of diabetes was then monitored by urine glucose. The number 
of mice in each group is indicated in parentheses.JEM VOL. 204, January 22, 2007  197
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specifi  c for CD4, Foxp3, and Thy1.1, and numerous CD4+ 
Foxp3+ Thy1.1− cells were found in the lymphocytic infi  l-
trate (Fig. 6 E). As a positive control for Thy1.1 staining, the 
lymph node from a Thy1.1-expressing mouse was stained 
with the same antibodies (Fig. 6 F); isotype control staining 
gave minimal signals in all channels (not depicted). There-
fore, during long-term successful treatment, the donor T reg 
cells can no longer be found in the recipients, even at the dis-
ease sites.
We also depleted Thy1.1+ cells from two mice that had 
been successfully treated with Thy1.1+ T reg cells. This treat-
ment did not lead to diabetes, because blood glucose levels 
did not substantially change for 7 wk after depletion (Fig. 
S4 A, available at http://www.jem.org/cgi/content/full/
jem.20061631/DC1). As the Thy1.1+ cells were already al-
most undetectable, it was diffi   cult to prove that depletion was 
successful. However, we could use the same Thy1.1-specifi  c 
antibody to deplete Thy1.1+ cells from control Thy1.2 mice 
injected with 5 × 106 CD4+ Thy1.1+ cells (Fig. S 4 B).
In addition, CD4+ CD25high cells were sorted from 
treated mice, and these T reg cells were able to suppress pro-
liferation of CD4+ CD25− T cells from BDC2.5 mice when 
stimulated with anti-CD3 but not with BDC peptide, sug-
gesting that the majority of these cells were not BDC specifi  c 
(unpublished data). Collectively, this suggests that the injected 
T reg cells were not sustained in large numbers but allowed 
endogenous T reg cells to maintain a favorable ratio of Foxp3+ 
cells to Foxp3− cells.
D  I  S  C  U  S  S  I  O  N 
Treatment of autoimmunity at late pathogenic stages
Individuals with a high risk for developing diabetes can be 
identifi  ed by genetic markers and the presence of high affi   n-
ity islet autoantibodies (32, 33), and at the time of diagnosis, 
type 1 diabetes patients retain  10% of their normal β cell 
mass (34). Therefore, inducing T cell tolerance and halting 
immune-mediated destruction at these two stages of disease 
may contribute to successful therapy for type 1 diabetes 
Figure 6.  Thy1.1+ BDC T reg cells do not persist after successful 
treatment of diabetes. (A and B) Diabetic NOD Thy1.2 mice successfully 
treated with 106 Thy1.1 BDC T reg cells were harvested 50 d after T reg 
cell injection (10 d after insulin pellets were removed). The percentage of 
lymphocytes in the pancreatic lymph node (A) or the pancreas (B) that are 
either CD4+ Thy1.1+ or CD4+ Thy1.1− are shown. (C and D) 12-wk-old 
nondiabetic Thy1.2 NOD mice were injected with nothing (left) or 
106 CD62L− (middle) or CD62L+ (right) T reg cells from BDC Thy1.1 mice. 
The percentages of lymphocytes 7 d later in the pancreatic lymph node 
(C) or the pancreas (D) that are either CD4+ Thy1.1+ or CD4+ Thy1.1− are 
shown. (E and F) Pancreas from diabetic NOD Thy1.2 mice successfully 
treated with Thy1.1 BDC T reg cells (E) or pancreatic lymph node of pre-
diabetic NOD Thy1.1 mice (F) were stained for CD4 (green), Foxp3 (red), 
and Thy1.1 (blue).198  DC-EXPANDED BDC2.5 T REG CELLS REVERSE DIABETES IN NOD MICE | Tarbell et al.
  patients. In this study, we addressed T reg cells as inducers of 
tolerance, but in contrast to most previous studies, we as-
sessed the capacity of T reg cells to treat established autoim-
munity rather than prevent it. In the one previous example 
of natural T reg cells treating spontaneous diabetes, 107 islet-
specifi  c T reg cells were used, an amount almost 10-fold 
higher than that used in this study (14). We show that islet-
specifi  c T reg cells, but not polyclonal T reg cells, can be used 
to treat autoimmune diabetes in NOD mice months after in-
sulitis has begun and even after overt diabetes has developed. 
These T reg cells have been expanded in number by DCs 
presenting a specifi  c peptide. This type of expansion of T reg 
cells by DCs also happens in vivo (9) and represents an im-
portant control of the number and, potentially, function of 
T reg cells.
In the prediabetic mice, CD62L+ but not CD62L− T reg 
cells were able to inhibit diabetes development (Fig. 2). The 
CD62L+ T reg cells may be more effi   cacious, because the 
CD62L− population may contain more recently activated T 
cells; alternatively, it is possible that, because CD62L is a 
homing marker for lymph node traffi   cking, the T reg cells 
must home to lymph nodes to gain effi   cacy. Supporting this 
second possibility, 7 d after transfer of 106 Thy1.1+ T reg 
cells sorted initially on either CD62L+ or CD62L− cells, 
fewer Thy1.1+ cells were found in the pancreatic lymph 
node of mice injected with CD62L− T reg cells (Fig. 6 C). 
Interestingly, CD6L− cells were also found in lower numbers 
in the pancreas (Fig. 6 D), suggesting that CD62L is necessary 
for T reg cells to home fi  rst to the lymph node before traf-
fi  cking to the infl  amed tissue.
Limited evidence exists for the therapeutic role of T reg 
cells in other autoimmune models. In two diff  erent mouse 
models of colitis induced by injection of pathogenic T cells 
into lymphopoenic mice, T reg cells given after development 
of severe intestinal infl  ammation could reverse colitis (35, 
36). In experimental autoimmune encephalitis, although 
transfer of T reg cells has not been shown to reverse disease, 
spontaneous remission correlated with increased numbers of 
endogenous T reg cells in the central nervous system, sug-
gesting a role for T reg cells in the natural recovery of estab-
lished autoimmunity (37).
Restoration of insulin production in new-onset diabetes
Rescue of insulin production is another important aspect of 
treatment of diabetes. Islet cell transplant can increase insu-
lin production but requires demanding immunosuppressive 
drugs to maintain transplantation tolerance. In addition, do-
nors are limited, making this an option for only a small frac-
tion of type 1 diabetic patients (38). In our experiments, 50% 
of newly diabetic mice were successfully treated with T reg 
cells without islet transplant. Interestingly, the T reg cell–
treated diabetic mice resemble prediabetic mice in both blood 
glucose levels and response to glucose challenge, suggesting 
considerable restoration of β cell function. Those mice in 
which blood glucose remained high may have had too few 
remaining insulin-producing cells such that even with toler-
ance induction, these mice would not recover. Signifi  cantly 
lower starting blood glucose levels in mice in which the 
treatment worked supports the idea that β cell mass, and not 
tolerance induction, was limiting the success rate of treat-
ment with islet-specifi  c T reg cells (Fig. 3 C).
We also tested the eff  ects of GLP-1, because it can in-
crease β cell proliferation and decrease β cell apoptosis, as 
well as have metabolic eff   ects that lower insulin require-
ments, probably allowing β cells to rest (39). However, addi-
tion of GLP-1 or exendin-4 did not improve the fraction of 
diabetic mice successfully treated with T reg cells, in contrast 
to some recently reported fi  ndings (5, 40). One possible ex-
planation for the observed diff  erences is that GLP-1 cannot 
promote diff  erentiation from precursors; in this case, if mice 
did not have enough β cells remaining, GLP-1 would not 
increase the effi   cacy of T reg cell treatment. In addition, the 
absence of GLP-1 eff  ects may be caused by the extremely 
short in vivo half-life of GLP-1 (41). Although exendin-4 is 
more stable in vivo, it is a peptide of nonmammalian origin, 
and its continuous administration may lead to the production 
of neutralizing antibodies. New GLP-1 analogues with in-
creased half-lives may help clarify this issue. β cell growth 
factors may be important for the restoration of endogenous 
insulin production without islet transplant as long as auto-
immunity can be contained with T reg cells. For example, 
the addition of gastrin, which has also been shown to increase 
β cell proliferation, may improve the effi   cacy of T reg cell 
treatment of diabetes (42, 43).
Expansion of T reg cells in diabetic recipients
Diabetic mice treated with T reg cells have higher numbers 
of Foxp3+ cells in lymph nodes compared with either predi-
abetic or diabetic NOD females. Although immediately af-
ter injection BDC T reg cells divide and expand in the 
pancreatic lymph node, when examined 50 d after treat-
ment, the increased Foxp3+ cells in the treated mice derive 
almost entirely from the recipient diabetic mice and not 
from the injected cells. This was seen in both the pancreatic 
lymph node and the pancreas. We suspect that the initial ex-
pansion of islet-specifi  c T reg cells sets up a regulatory envi-
ronment in the pancreas and draining lymph node that 
encourages either expansion or diff  erentiation of endoge-
nous T reg cells to balance out the increased numbers of 
pathogenic cells likely found in diabetic mice. The ability of 
splenocytes from successfully treated mice to transfer diabe-
tes suggests that a dominant, nondeletional tolerance mecha-
nism is important. Interestingly, it was previously shown 
that transient expression of TGF-β in the pancreas of NOD 
mice leads to protection for diabetes development and in-
duction of T reg cells (44).
In some other experimental systems, injected T reg cells 
are necessary for maintenance of tolerance. For example, 
  antigen-induced Thy1.1+ T reg cells prevent autoimmune 
ovarian disease. In this system, considerable numbers of the 
Thy1.1+ T reg cells are maintained long term, but disease re-
turns if the Thy1.1+ T cells are depleted (45). Similar results JEM VOL. 204, January 22, 2007  199
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were found in a mouse model of multiple sclerosis (46). 
However, induction of new T reg cells by other T reg cells 
has been proposed and may involve TGF-β or other cyto-
kines, as has been shown in vitro (47). In transplantation, 
anti-CD4 blockade in mice devoid of natural T reg cells leads 
to acceptance of allogeneic skin grafts. This tolerance is TGF-β 
dependent and involves the induction of Foxp3+ cells, but 
doesn’t directly show one T reg cell population inducing a 
new population of T reg cells (48, 49).
Our fi  ndings represent the fi  rst demonstration of a de-
fi  ned set of natural T reg cells inducing new T reg cells in 
vivo. The injected T reg cells could have a direct eff  ect on 
expansion or diff  erentiation of new T reg cells through cyto-
kine or co-stimulatory molecules. It is also possible that the 
injected T reg cells “license” the DCs in the pancreas or 
draining lymph node in a way that improves the ability of 
these DCs to expand or diff  erentiate new T reg cells. These 
results also show that T reg cells can be expanded from dia-
betic mice, which may allow the design of antigen-specifi  c 
therapies in new-onset diabetic patients.
In summary, the experiments described in this paper show 
that T cell tolerance induced by DC-expanded, islet-specifi  c 
T reg cells can both increase endogenous T reg cells and 
  reverse autoimmune diabetes in NOD mice. This antigen-
  specifi  c therapy can now be added to the short list of mostly 
nonspecifi  c methods for reversing diabetes, including anti-
CD3 and TGF-β, which may work through induction of 
T reg cells (50). These results, in conjunction with our previous 
report, reiterate the role for DCs in expanding disease-treating 
T reg cells. Given the fact that DCs expand disease-suppressive, 
antigen-specifi  c T reg cells, a study of these interacting cells 
could be informative.
MATERIALS AND METHODS
Mice. NOD mice and BDC2.5 TCR transgenic mice on the NOD genetic 
background were purchased from the Jackson Laboratory and bred under 
specifi  c pathogen-free conditions at the Rockefeller University. Mice of 
both sexes were used at the indicated ages according to our institutional 
guidelines. Protocols were approved by the Institutional Animal Care and 
Use Committee.
Antibodies and staining. Antibodies specifi  c for: Gr1 (RB6-8C5), CD4 
(H129.19), CD86 (GL1), CD25 (7D4), CD62L (MEL-14), CD25 (PC61), 
CD4 (RM4-5), and Thy1.1 (OX-7); and isotype controls, 7-amino-
  actinomycin D, and PE-streptavidin were purchased from BD Biosciences. 
Streptavidin–Pacifi  c blue was purchased from Invitrogen. Anti-Foxp3 (FJK-16s) 
conjugated to PE or APC was purchased from eBioscience. A hybridoma 
expressing the anticlonotype antibody specifi  c for the BDC2.5 TCR (BDC) 
was provided by O. Kanagawa (Washington University, St. Louis, MO), and 
the antibody was purifi  ed and biotinylated. All staining was done according 
to standard protocols.
Purifi   cation and DC-based expansion of regulatory cells. Bone 
  marrow–derived DCs from NOD mice were matured with LPS and en-
riched for CD86+ cells using magnetic beads, as described previously (9). 
T cells were purifi  ed from lymph nodes and spleens from BDC2.5 NOD 
mice by fi  rst labeling with anti-CD4–FITC, CD62L-APC, and CD25-
  biotin, followed by streptavidin-PE and enriching for CD25+ cells with 
magnetic beads coated with PE-specifi  c antibodies (Miltenyi Biotec). CD4+ 
CD25+ CD62L+ or CD4+ CD25+ CD62L− cells were then sorted to 
>98% purity. The T cells and DCs were cultured at a ratio of 1:1, as previ-
ously described (9), for 6–8 d with 100 ng/ml BDC mimetope peptide 
(termed 1040–55; sequence R  V  R  P  L  W  V  R  M  E  ) (12) and 200 U/ml rHuIL2 
(Chiron Corp). Unless otherwise indicated, the T reg cells used in this 
study are CD4+ CD25+ CD62L+ cells from BDC2.5 NOD mice expanded 
with DCs.
Diabetes experiments. Treatment of prediabetic mice was as follows. 
13-wk-old nondiabetic female NOD mice were given the numbers of DC-
expanded T reg cells via i.v. injection indicated in the fi  gures, and diabetes 
was monitored by urine glucose once per week. Diabetes was defi  ned as 
three consecutive positive readings.
Treatment of diabetic NOD mice was as follows. To have an average of 
5–10 newly diabetic mice at any one time, we have followed a cohort of 
 200–300 NOD females between 12–30 wk old. Diabetic NOD females 
were identifi  ed by urine glucose and confi  rmed by a blood glucose reading 
>250 mg/dl. Within each experiment, these starting blood glucose levels 
were matched between groups. Insulin pellets were then implanted s.c. as 
needed to maintain blood glucose <250 mg/dl for 40 d and removed. Each 
pellet contains 13 mg of insulin and continuously releases  0.1 unit/   implant 
(LinShin Canada, Inc.). In the groups indicated, mice were injected on 
days 0 and 14 with 0.8–1.5 × 106 BDC T reg cells by i.v. injection and with 
50 ng exendin-4 (Bachem) on days 0, 1, 2, 7, 8, and 9 by i.p. injection. The 
subsequent development of diabetes was monitored by blood glucose read-
ings two to three times per week. All mice denoted in the fi  gures as respond-
ers, successfully treated, or T reg treated were followed for a minimum of 
2 mo and for as long as 6 mo after removal of exogenous insulin. For the ex-
periment shown in Fig. 3 A, NOD females with diabetes were identifi  ed by 
urine glucose within 5 d of onset and given insulin via pellets that secrete 
continuously for  3 wk. All mice received i.p. injection of 5 μg GLP-1 
(Bachem) on days 2, 3, 5, 11, 16, 23, 25, and 29. Within 3 d of receiving the 
insulin pellet, one group was injected i.v. with 1.5 × 106 DC-expanded 
CD4+ CD25+ CD62L+ cells isolated from BDC2.5 mice.
Depletion with anti-Thy1.1. 100 μg anti-Thy1.1 (clone HIS51) was 
given i.v., and expression of Thy1.1 after depletion was monitored using 
anti-Thy1.1 (clone OX-7) at the times indicated in the fi  gures.
Glucose tolerance test. Mice were kept without food for 15 h and were 
given 2 mg of glucose per gram of bodyweight i.p. Blood glucose was moni-
tored at the intervals indicated in Fig. 4 A for 90 min.
Histology. Insulitis and sialitis were checked by observing lymphocytic 
infi  ltrates in the pancreatic islets or salivary glands using hematoxylin and 
eosin sections. Insulitis was scored as follows: no insulitis, periinsulitis, intra-
insulitis with <70% of the islet infi  ltrated, or intrainsulitis with >70% of the 
islet infi  ltrated.
Immunofl  uorescence. Tissue was frozen in optimal cutting temperature 
compound. 10-μm sections were air dried and fi  xed in acetone. Sections 
were stained with anti-Thy1.1–FITC (Ox-7), anti-FITC–Alexa Fluor 488 
(Invitrogen), Foxp3-PE, anti–rat–Alexa Fluor 546 (Invitrogen), and CD4–
Alexa Fluor 647 (L3T4; BD Biosciences) or isotype controls and blocked 
with 5% mouse serum and 2–5% rat serum. Images were acquired on an in-
verted laser scanning confocal microscope (LSM 510; Carl Zeiss MicroImaging, 
Inc.) using a 40× objective.
Statistics. Comparisons of groups in Fig. 3 D were analyzed by Fisher’s 
  exact test. Groups in Fig. 2 were compared by the Mann-Whitney U test. 
Groups in Fig. 3 C, Fig. 4 B, and Fig. 5 B were compared using a t test.
Online supplemental material. Fig. S1 shows an additional example of 
treatment of diabetic mice with T reg cells and exendin-4. Fig. S2 shows blood 
glucose levels of female NOD mice from 13 to 25 wk of age. Fig. S3 shows 
insulitis levels in T reg cell–treated diabetic mice. Fig. S4 shows the results of 200  DC-EXPANDED BDC2.5 T REG CELLS REVERSE DIABETES IN NOD MICE | Tarbell et al.
depletion of Thy1.1+ cells with anti-Thy1.1. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20061631/DC1.
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